Rheos Medicines Appoints Nirupama Subramanian as Chief Operating Officer

Brings leadership experience from Agios Pharmaceuticals and Novartis Vaccines with strategy and operations expertise across many stages of product development and company growth

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Rheos Medicines, a biopharmaceutical company transforming the treatment of autoimmune disease through its metabolic precision medicine platform, today announced the appointment of Nirupama Subramanian as Chief Operating Officer. In this role on the Rheos executive leadership team, Ms. Subramanian will be responsible for finance, corporate development, program and portfolio management, alliance management, legal and facilities, as well as playing a key role in developing the company’s business strategy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210809005116/en/

Rheos COO Niru Subramanian (Photo: Business Wire)

“We are very pleased to welcome Niru to our leadership team. She brings a wealth of operations, strategic planning and corporate development expertise that will be immensely valuable to Rheos as we grow our business and evolve into a clinical-stage company,” said Barbara Fox, Ph.D., Chief Executive Officer of Rheos Medicines. “We look forward to benefiting from Niru’s strategic acumen and breadth of knowledge across drug development as we continue to advance our lead program into the clinic next year and explore the full potential of our platform to build a new generation of precision medicines for autoimmune and inflammatory diseases.”

Ms. Subramanian brings over 20 years of business and corporate development experience to Rheos, including building new strategies and capabilities for high-growth organizations, leading multifunctional teams, managing partnerships and M&A transactions, and directing portfolio planning, alliance management, finance and operations. Most recently, she served as Senior VP, Corporate Development & Business Planning at Agios Pharmaceuticals, where she played an integral role in shaping the company’s strategy and led several key initiatives including the $2 billion sale of Agios’ oncology business in December 2020. Previously, Ms. Subramanian worked for eight years at Novartis Vaccines, including as Vice President, Head of Influenza Global Programs, with responsibility for clinical development of pipeline assets, product launch preparations, lifecycle management, and sales and profitability for the influenza vaccine franchise. She also served at Novartis as Vice President, Vaccines Business Transition Lead, a role in which she managed the transition of the influenza vaccines business during divestment from Novartis following its sale in October 2014. Earlier in her career, she worked at The Boston Consulting Group in their healthcare practice area advising large and small biopharma companies on a variety of strategic and operational issues. Ms. Subramanian received a BS from the University of Pennsylvania and an MBA from the Harvard Business School.

“This is an exciting time to join Rheos as the company embarks on a growth trajectory across many fronts: advancing its lead drug program to the clinic, continuing to make progress with its pipeline of precision medicines, as well as further building its differentiated platform for drug discovery and development. I am eager to leverage my experience to help the company achieve its goals as a precision medicine innovator for patients with autoimmune and inflammatory diseases,” said Ms. Subramanian.

About Rheos Medicines

Rheos Medicines is a biopharmaceutical company harnessing insights in immunometabolism to develop novel therapeutics for patients with severe immune-mediated diseases. Our approach targets the underlying intracellular metabolism of immune cells and has the potential to unlock a new frontier in drug discovery for immune-mediated disease. Through a proprietary platform and product engine that integrates multiple “omic” datasets, we systematically define the biologic links between immune cell metabolism and function and simultaneously identify new drug targets and biomarkers of disease to bring precision to the treatment of immune-mediated diseases. We have assembled leading scientists whose discoveries opened the field of immunometabolism, clinicians with a deep understanding of immune-mediated diseases, and an experienced biotech leadership team. Rheos was founded by Third Rock Ventures and is located in Cambridge, MA. For more information, please visit www.rheosrx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210809005116/en/